Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides

Cham, Bill E.; Daunter, B.; Evans, R

doi:10.1016/0304-3835(91)90140-d

Cited by 88 publications

(75 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These observations are in stark contrast to other well established anti-mitotic chemotherapy drugs that only kill cancer cells while they are dividing and also kill normal cells when they too are dividing [40][41][42][43][44][45][46][47][48].…”

Section: Kill Cancer Cells In Proliferative and Non-proliferative Stamentioning

confidence: 93%

“…Subsequently clinical trials using 10% of BEC in a cream formulation determined that this formulation was effective for the treatments of keratoses, BCCs and SCCs [46]. More recently clinical trials with Curaderm BEC5 containing 0.005% BEC showed impressive results when, even very large nonmelanoma skin cancers were treated [2,27,34,38,[41][42][43][44][54][55][56]. BEC present in Curaderm BEC5 is at a much lower concentration than is found naturally in the eggplant [10].…”

Section: Bec5 Are More Effective and Safer Than Other Well Establishementioning

confidence: 99%

“…However, the eggplant also contains anticancer inhibitors which must be removed in order to obtain the anticancer benefits shown with Curaderm BEC5 therapy. Accordingly, and as shown by many studies, BEC in Curaderm BEC5 is very safe [2,9,27,34,38,[41][42][43][44][54][55][56].…”

Section: Bec5 Are More Effective and Safer Than Other Well Establishementioning

confidence: 99%

“…BEC5 have demonstrated that there are no adverse effects on the liver, kidneys or haematopoietic system during treatment [2,7,26,34,41,43,44,[47][48][49][54][55][56].…”

Section: Studies With Curadermmentioning

confidence: 99%

See 3 more Smart Citations

Curaderm<sup>BEC5</sup> for Skin Cancers, Is It? An Overview

Chase¹

2011

JCT

View full text Add to dashboard Cite

show abstract

Section: Kill Cancer Cells In Proliferative and Non-proliferative Stamentioning

confidence: 93%

Section: Bec5 Are More Effective and Safer Than Other Well Establishementioning

confidence: 99%

Section: Bec5 Are More Effective and Safer Than Other Well Establishementioning

confidence: 99%

“…BEC5 have demonstrated that there are no adverse effects on the liver, kidneys or haematopoietic system during treatment [2,7,26,34,41,43,44,[47][48][49][54][55][56].…”

Section: Studies With Curadermmentioning

confidence: 99%

See 2 more Smart Citations

Curaderm<sup>BEC5</sup> for Skin Cancers, Is It? An Overview

Chase¹

2011

JCT

View full text Add to dashboard Cite

show abstract

“…Fourteen possible RCTs were identified for inclusion, of which 12 were fully published papers [520][521][522][523][524][525][526][527][528][529][530][531] and two were abstracts. 532,533 However, only one RCT met the inclusion criteria for this review.…”

Section: Randomised Controlled Trials Included In This Reviewmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract